[Monitoring of antiplatelet drug effects--fashion or necessity?].
Kuliczkowski
Wiktor
W
III Katedra i Oddział Kliniczny Kardiologii, Slaskie Centrum Chorób Serca, ul. Szpitalna 2, 41-800 Zabrze. wiktor6@wp.pl
Zembala
Marian
M
Poloński
Lech
L
Kaczmarski
Jacek
J
Gasior
Mariusz
M
D000074:Acenocoumarol / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D000077144:Clopidogrel; D016903:Drug Monitoring; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019934:International Normalized Ratio; D010314:Partial Thromboplastin Time; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D010979:Platelet Function Tests; D011517:Prothrombin Time; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D000077144:Clopidogrel; D000074:Acenocoumarol; D013988:Ticlopidine; D001241:Aspirin